We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Indian Regulators Seek Details on Orthopedic Implant Pricing

Indian Regulators Seek Details on Orthopedic Implant Pricing

July 10, 2015

India’s National Pharmaceutical Pricing Authority is asking several orthopedic implant manufacturers to provide details on cost increases that potentially may violate drug pricing laws.

In a letter addressed to executives at pharmaceutical associations and device manufacturers, NPPA asks for a brief description of the products, the maximum retail price and the percent increase in the MRP for each of the last three years. The regulator is looking into possible violations of the Drug Pricing Control Order of 2013, which states that no manufacturer, importer or distributor may raise the MRP of a nonscheduled drug more than 10 percent during the preceding 12 months.

According to the letter, the companies had sought clarification on whether DPCO 2013 provisions apply to medical devices, something NPPA confirms. “Orthopedic implants along with other medical devices are notified as ‘Drug’ under the Drugs & Cosmetic Act 1940 and rules thereunder,” the letter states.

The rules authorize the government to inspect price list records, including those of 14 notified medical devices. NPPA asks the associations to encourage their member companies to provide the information within seven days of receipt of the letter.

The authority previously asked for this information in a May 15 notice that highlighted media reports alleging orthopedic implants have been sold at exorbitant prices with high profit/trade margins.

The letter comes as industry continues its ongoing push for a distinct definition of medical devices and a pricing and reimbursement system separate from that of drugs. The government took a step in that direction last month by announcing the creation of a dedicated authority to oversee the regulation and production of medical devices. Industry groups may comment on the government proposal through July 15 (IDDM, June 12).

The latest NPPA letter is available here: www.fdanews.com/071315-NPPA-request.pdf. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing